Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, Anavex Life Sciences Corp did not generate a significant amount of cash. Cash Flow from Financing totalled 29.65m or -- of revenues. In addition the company used 27.79m for operations while cash used for investing totalled .
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 1.53 |
---|---|
Tangible book value per share | 1.53 |
More ▼
Balance sheet in USDView more
Current ratio | 12.04 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼